Want to see HK:1167 full AI Analyst Report?
Top Page
Jacobio Pharmaceuticals Group Co., Ltd.
(1167)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$5.00
▼(-37.97% Downside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by weak financial performance (sharp 2025 revenue contraction, persistent losses, and ongoing negative free cash flow/cash burn), reinforced by bearish technicals (price below all major moving averages and negative MACD). Valuation provides only a limited offset since the negative P/E reflects losses and no dividend yield is available.
Positive Factors
Manageable leverage / balance-sheet flexibility
Low reported debt-to-equity provides durable financial flexibility for a clinical-stage biotech. With manageable leverage the company can fund ongoing R&D or bridge financings without immediate refinancing pressure, lowering near-term default risk and preserving optionality for partnerships or milestone-driven inflows.
Negative Factors
Sharp recent revenue contraction
A ~74% top-line decline materially reduces revenue visibility and weakens the company’s ability to fund operations internally. Such a contraction typically reflects program delays or reduced partner income and increases dependency on external financing, which can slow clinical progress and strategic execution over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage / balance-sheet flexibility
Low reported debt-to-equity provides durable financial flexibility for a clinical-stage biotech. With manageable leverage the company can fund ongoing R&D or bridge financings without immediate refinancing pressure, lowering near-term default risk and preserving optionality for partnerships or milestone-driven inflows.
Read all positive factors
Jacobio Pharmaceuticals Group Co., Ltd. (1167) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.66B
Dividend YieldN/A
Average Volume (3M)7.94M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-65.87%
EPS Growth6.71%
CountryHK
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio3.18
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$723.51M
Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model
Company Description
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src hom...
How the Company Makes Money
Jacobio Pharmaceuticals generally makes money through (1) collaboration and licensing arrangements, where it grants partners rights to develop and/or commercialize specific drug candidates in certain territories in exchange for upfront payments, d...
Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.14M | 155.71M | 63.52M | 95.75M | 152.81M |
| Gross Profit | 29.35M | 155.71M | 3.20M | 12.63M | 12.83M |
| EBITDA | -143.46M | -192.36M | -325.73M | -355.80M | -289.83M |
| Net Income | -142.20M | -155.71M | -359.12M | -371.86M | -301.19M |
Balance Sheet | |||||
| Total Assets | 1.30B | 1.36B | 1.46B | 1.57B | 1.72B |
| Cash, Cash Equivalents and Short-Term Investments | 1.10B | 1.17B | 1.15B | 1.28B | 1.54B |
| Total Debt | 165.24M | 152.08M | 209.91M | 147.79M | 6.81M |
| Total Liabilities | 533.92M | 435.99M | 387.11M | 292.12M | 84.75M |
| Stockholders Equity | 770.96M | 923.18M | 1.07B | 1.28B | 1.64B |
Cash Flow | |||||
| Free Cash Flow | -187.27M | -86.21M | -402.86M | -308.92M | -158.63M |
| Operating Cash Flow | -186.20M | -74.12M | -364.20M | -292.42M | -147.49M |
| Investing Cash Flow | -138.63M | 256.22M | -48.00M | -686.32M | 161.67M |
| Financing Cash Flow | 45.20M | 21.28M | 246.28M | -9.85M | 109.06M |
Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis
Negative
8.06
Price Trends
4.97
Negative
5.91
Negative
6.72
Negative
Market Momentum
0.03
Negative
44.29
Neutral
51.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Negative. The current price of 8.06 is above the 20-day moving average (MA) of 4.80, above the 50-day MA of 4.97, and above the 200-day MA of 6.72, indicating a bearish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 44.29 is Neutral, neither overbought nor oversold. The STOCH value of 51.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1167.
Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.78B | 6.90 | 2.04% | ― | 1117.02% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$2.59B | -9.32 | -26.73% | ― | 14.59% | 22.41% | |
46 Neutral | HK$6.77B | -55.96 | -6.26% | ― | -11.65% | -169.40% | |
45 Neutral | HK$3.66B | -21.61 | -17.64% | ― | -65.87% | 6.71% | |
44 Neutral | HK$13.25B | -8.95 | -123.74% | ― | -41.32% | -159.81% | |
41 Neutral | HK$7.15B | -18.67 | -64.78% | ― | -33.37% | -344.90% |
* Healthcare Sector Average
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.65
-2.46
-34.60%
HK:6996
Antengene Corporation Limited
4.09
-0.29
-6.62%
HK:6998
Genor Biopharma Holdings Limited
1.88
-0.80
-29.85%
HK:9966
Alphamab Oncology
6.95
-1.74
-20.02%
HK:2616
CStone Pharmaceuticals
4.53
-2.00
-30.63%
HK:6855
Ascentage Pharma Group International
35.76
-41.69
-53.83%
Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events
Jacobio Pharmaceuticals Launches HK$100 Million Share Buyback Plan
Jun 8, 2026
Jacobio Pharmaceuticals has announced plans to repurchase up to 78,372,528 shares, equivalent to 10% of its issued share capital, under an existing general mandate approved at its June 2026 annual meeting. The company will allocate up to HK$100 mi...
Jacobio Shareholders Back All Resolutions at 2026 AGM, Renewing Capital Mandates
Jun 5, 2026
Jacobio Pharmaceuticals reported that all resolutions at its 5 June 2026 annual general meeting were approved by shareholders via poll voting, with 783,725,280 shares entitled to vote and no special restrictions on participation. The meeting confi...
Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances
May 18, 2026
Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury shares at a total cost of about HK$34.17 million. The board argues that the current share price undervalues the company...
Jacobio Pharmaceuticals Sets 2026 AGM, Seeks Fresh Share Issuance Mandate
Apr 24, 2026
Jacobio Pharmaceuticals has called its 2026 annual general meeting for June 5, 2026, in Beijing, where shareholders will review and adopt the company’s audited financial statements and directors’ and auditor’s reports for the yea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.